Monday, 17 August 2009 00:00
Clinical Data, Inc. (NASDAQ: CLDA), today announced a collaboration and licensing agreement with CombinatoRx, Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma, and other B-cell cancers. Under the agreement, Clinical Data licensed its highly selective adenosine A2A agonist, ATL313,
to CombinatoRx in exchange for the potential to receive up to $252 million in clinical, regulatory and commercial milestones, as well as royalties on product sales. Clinical Data also retains a co-development option, which is exercisable after review of any Phase IIa study results.
As part of the agreement, Clinical Data will contribute ATL313, a promising late-stage, preclinical compound. Under the collaboration, CombinatoRx will be responsible for the preclinical and clinical development of ATL313 to potentially treat B-cell malignancies.
Research has shown that a combination drug approach utilizing adenosine A2A agonists as a component of a combination therapy could be beneficial in the treatment of multiple myeloma. Initial results from studies utilizing this approach have been presented by CombinatoRx and demonstrated:
• broad activity in multiple myeloma cell lines
• synergy with multiple myeloma standard-of-care therapies
• potent induction of apoptosis (cancer cell death)
• selectivity and safety with broad therapeutic window over normal cells
"Adenosine A2A agonists have shown tremendous promise in the development of therapeutics to treat a variety of diseases including cancer, inflammation, and pain disorders,” said Drew Fromkin, President and CEO of Clinical Data. “We are pleased to continue to leverage the value of our highly selective adenosine pipeline by working with CombinatoRx to develop new therapies for multiple myeloma and other B-cell malignancies.”
About Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in the US and although the disease is predominantly a cancer of the elderly (most people with MM are diagnosed after age 65), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.
About Clinical Data, Inc.
Clinical Data develops first-in-class and best-in-category targeted therapeutics. The Company is advancing its late-stage drug candidates for central nervous system disorders and cardiovascular diseases to be followed by promising drug candidates in major therapeutic areas including oncology and inflammatory diseases. Clinical Data plans to differentiate its therapeutics by helping to predict and enhance efficacy and tolerability by combining its drug development and biomarker expertise to improve patient health and reduce costs. To learn more, please visit the Company's website at www.clda.com.